Analysis of factors that affect in vitro chemosensitivity of leukaemic stem and progenitor cells to gemtuzumab ozogamicin (Mylotarg) in acute myeloid leukaemia. (Q53369470)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Analysis of factors that affect in vitro chemosensitivity of leukaemic stem and progenitor cells to gemtuzumab ozogamicin (Mylotarg) in acute myeloid leukaemia.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/19776761

Analysis of factors that affect in vitro chemosensitivity of leukaemic stem and progenitor cells to gemtuzumab ozogamicin (Mylotarg) in acute myeloid leukaemia. (English)

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/19776761

1 reference

based on heuristic

inferred from title

Claire Seedhouse

2

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/19776761

author name string

M Jawad

1

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/19776761

U Mony

3

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/19776761

M Grundy

4

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/19776761

N H Russell

5

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/19776761

M Pallis

6

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/19776761

publication date

24 September 2009

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/19776761

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/19776761

24

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/19776761

1

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/19776761

74-80

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/19776761

The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells

1 reference

https://api.crossref.org/works/10.1038/LEU.2009.199

21 January 2018

Detection of molecular targets on the surface of CD34 /CD38-- stem cells in various myeloid malignancies.

1 reference

https://api.crossref.org/works/10.1038/LEU.2009.199

21 January 2018

Resistance to FLT3 inhibition in an in vitro model of primary AML cells with a stem cell phenotype in a defined microenvironment.

1 reference

https://api.crossref.org/works/10.1038/LEU.2009.199

21 January 2018

Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038/LEU.2009.199

21 January 2018

Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin

1 reference

https://api.crossref.org/works/10.1038/LEU.2009.199

21 January 2018

CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy

1 reference

https://api.crossref.org/works/10.1038/LEU.2009.199

21 January 2018

DNA repair contributes to the drug-resistant phenotype of primary acute myeloid leukaemia cells with FLT3 internal tandem duplications and is reversed by the FLT3 inhibitor PKC412.

1 reference

https://api.crossref.org/works/10.1038/LEU.2009.199

21 January 2018

The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the Unite

1 reference

https://api.crossref.org/works/10.1038/LEU.2009.199

21 January 2018

The roles of FLT3 in hematopoiesis and leukemia

1 reference

https://api.crossref.org/works/10.1038/LEU.2009.199

21 January 2018

Internal tandem duplications of the FLT3 gene are present in leukemia stem cells

1 reference

https://api.crossref.org/works/10.1038/LEU.2009.199

21 January 2018

An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells.

1 reference

https://api.crossref.org/works/10.1038/LEU.2009.199

21 January 2018

Multidrug resistance protein attenuates gemtuzumab ozogamicin-induced cytotoxicity in acute myeloid leukemia cells.

1 reference

https://api.crossref.org/works/10.1038/LEU.2009.199

21 January 2018

P-glycoprotein in acute myeloid leukaemia: therapeutic implications of its association with both a multidrug-resistant and an apoptosis-resistant phenotype

1 reference

https://api.crossref.org/works/10.1038/LEU.2009.199

21 January 2018

High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival

1 reference

https://api.crossref.org/works/10.1038/LEU.2009.199

21 January 2018

Influence of CD33 expression levels and ITIM-dependent internalization on gemtuzumab ozogamicin-induced cytotoxicity

1 reference

https://api.crossref.org/works/10.1038/LEU.2009.199

21 January 2018

Internalization and cell cycle-dependent killing of leukemic cells by Gemtuzumab Ozogamicin: rationale for efficacy in CD33-negative malignancies with endocytic capacity

1 reference

https://api.crossref.org/works/10.1038/LEU.2009.199

21 January 2018

Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells

1 reference

https://api.crossref.org/works/10.1038/LEU.2009.199

21 January 2018

Granulocyte colony-stimulating factor enhances the in vitro cytotoxicity of gemtuzumab ozogamicin against acute myeloid leukemia cell lines and primary blast cells.

1 reference

https://api.crossref.org/works/10.1038/LEU.2009.199

21 January 2018

Cytotoxic activity of gemtuzumab ozogamicin (Mylotarg) in acute myeloid leukemia correlates with the expression of protein kinase Syk.

1 reference

https://api.crossref.org/works/10.1038/LEU.2009.199

21 January 2018

Expression of the target receptor CD33 in CD34 /CD38-/CD123 AML stem cells

1 reference

https://api.crossref.org/works/10.1038/LEU.2009.199

7 January 2021

based on heuristic

inferred from DOI database lookup

Aberrant marker expression patterns on the CD34 CD38- stem cell compartment in acute myeloid leukemia allows to distinguish the malignant from the normal stem cell compartment both at diagnosis and in remission

1 reference

https://api.crossref.org/works/10.1038/LEU.2009.199

7 January 2021

based on heuristic

inferred from DOI database lookup

Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038/LEU.2009.199

7 January 2021

based on heuristic

inferred from DOI database lookup

A monoclonal antibody reactive with normal and leukemic human myeloid progenitor cells

1 reference

https://api.crossref.org/works/10.1038/LEU.2009.199

7 January 2021

based on heuristic

inferred from DOI database lookup

Calicheamicin gamma 1I: an antitumor antibiotic that cleaves double-stranded DNA site specifically

1 reference

https://api.crossref.org/works/10.1038/LEU.2009.199

7 January 2021

based on heuristic

inferred from DOI database lookup

Flow cytometric chemosensitivity analysis of blasts from patients with acute myeloblastic leukemia and myelodysplastic syndromes: the use of 7AAD with antibodies to CD45 or CD34

1 reference

https://api.crossref.org/works/10.1038/LEU.2009.199

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of gemtuzumab ozogamicin on acute myeloid leukemia blast cells in vitro, as a single agent and combined with other cytotoxic cells

1 reference

https://api.crossref.org/works/10.1038/LEU.2009.199

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse

1 reference

https://api.crossref.org/works/10.1038/LEU.2009.199

7 January 2021

based on heuristic

inferred from DOI database lookup

Minimal residual disease cells in AML patients have an apoptosis-sensitive protein profile

1 reference

https://api.crossref.org/works/10.1038/LEU.2009.199

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/LEU.2009.199

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/19776761

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/19776761

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53369470&oldid=2212094521"